StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) income statement

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.51+0.04 (+0.24%)

Close on Nov 18, 2026Market cap $3.62BP/E –Yield –

Relay Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-2999.4%
Net margin
-2763.6%
Return on equity, FY2025
-41.1%

Financial strength

Current ratio
18.27
Debt to equity
–
Debt to assets
–
Cash to current liabilities
238.5%

Valuation

P/E ratio
–
Price to sales
349.57
Price to book
4.07
Dividend yield
–

See a number that looks wrong?